SCHEMBL19084477

SCHEMBL19084477

O=c1cc(-c2ccc([N+](=O)[O-])cc2)[nH]c2c(-c3ccc(Cl)c(Cl)c3)c(-c3ccccc3)nn12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 8/20 0.50
ARF6 P62330 2/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
CYP19A1 P11511 1/20 0.41
BTK Q06187 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
CCR6 P51684 1/20 0.37
OPRK1 P41145 1/20 0.36
THRB P10828 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084479 0.90 PSD (0.48) PSDARF6KMT2AMEN1MAPT
SCHEMBL19084591 0.85 ARF6 (0.54) PSDARF6
SCHEMBL19084642 0.82 PSD (0.53) PSDARF6
SCHEMBL19084647 0.82 ARF6 (0.64) PSDARF6MAPTALDH1A1MCL1
SCHEMBL19084536 0.79 PSD (0.48) PSDKMT2AMEN1MAPTLMNA
SCHEMBL19084688 0.77 PSD (0.51) PSDARF6KMT2AMEN1MAPT
SCHEMBL19084599 0.77 PSD (0.52) PSDARF6KMT2AMEN1MAPT
SCHEMBL14899468 0.76 ARF6 (0.56) PSDARF6KMT2AMEN1MAPT
SCHEMBL19084648 0.76 PSD (0.53) PSDARF6KMT2AMEN1MAPT
SCHEMBL13516218 0.75 ARF6 (0.65) PSDARF6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885KMT2A 4004/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885KMT2A 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.